reviewBiochemical and Biophysical Research CommunicationsJun 6, 2005Closed access

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

NFNapoleone FerraraKJKenneth J. HillanWNWilliam Novotny

Molecular Oncology (United States)

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

973
total citations
FWCI
16.93
Percentile
100%
References
112
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Bevacizumab
  • Angiogenesis
  • Medicine
  • Vascular endothelial growth factor
  • Cancer research
  • Neovascularization
  • Monoclonal antibody
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.